Want more about Business to land in your mailbox?


Zydus Cadila registers 28% income growth in Q2
|
RSS feed for news |
During the second quarter ended September 30, 2007, Zydus Cadila reported a total income of Rs. 610 crore, up 28% from Rs. 475 crore in the corresponding quarter of the previous year, on a consolidated basis. The income growth was mainly driven by 122% growth in formulation exports and growth of 37% in consumer business. PBIDT was up by 21% to Rs. 132 crore during the quarter from Rs. 109 crore in the corresponding period last year. The net profit was up 14% to Rs. 80 crore from Rs. 71 crore in the second quarter of 2006-07.
During the quarter, the company’s subsidiaries in France and US registered a strong performance. Zydus France SAS, which currently markets over 100 generic presentations, registered 38% growth in sales. During the quarter, 3 dossiers for new products and 9 additional site transfer applications were filed with the French regulatory authority AFSSAPS.
In the US, the company’s sales grew by 123%. During the quarter, 3 new products were launched in the US – Benzonatate Capsules, Carvedilol Tablets and Amlodipine Besylate Tablets. The group filed 2 additional DMFs and 4 more ANDAs this quarter taking the total to 55 DMFs and 66 ANDA filings, of which 30 have been approved so far.
Further strengthening its research pipeline, the group filed its 5th IND ‘ZYH7’ - a novel drug candidate for treating dyslipidemia and metabolic disorders, during the quarter.
Sourced From: Pressman India


Business
Business News | Economy | Earnings | BSE NSE Notices
General News
Current Affairs | Politics | World News | Sports | Entertainment
Corporate Strategy
Management | Advertising | Marketing | Legal
Personal Finance
Tax | Insurance | Credit Cards | Loans | Property | Retirement | Investment Help | Financial Planning | Fixed Income
Markets
Local Market | Global Market | Market Cues | Analysis | Expert & FII outlook | Brokerage Recomendation
Stocks
Stocks in News | Expert Advice | ADRs & GDRs | IPO
Mutual Funds
News | Advice | MF Analysis | Fund Managers Views
Lifestyle
Travel | Wellness | Technology | Auto| Books
Harsh Manglik
Chairman
Accenture India
Accenture India to hire aggressively for select verticals
Vishal Doshi
Managing Director
Shrenju & Company
Shrenuj & Company will project 15% rev rise this yr
MP Taparia
Chairman
Supreme Petrochemicals
Supreme Petrochemicals expects Rs 2200cr rev in next 1.5yrs
Vineet Nayyar
Chief Executive Officer
HCL Technologies
HCL Tech plans to merge arms with itself, eyes new spots
-
Most Read
-
Most Viewed
- UBS Sec: Good level to enter mkts, suggests stocks

- Mitesh Thacker's top 5 picks for today's trade

- Nifty to cross 5100; infra, banking best bets: Quantum Sec

- End of BPLR: RBI to de-regulate lending rates in FY11

- ARSS Infrastructure IPO opens; should you subscribe?
- Jubilant Food's anchor investors buy add'l stake on debut
- SAIL to issue bonus shares before FPO: Sources

- Ten success stories in unheard of sectors
- What is Religare Capital betting on in the long-term?

- India a stock picker's market: JPMorgan Sec

- China confirmed as global export champion
Source: ft.com
- Time to understand how the mighty fall
Source: ft.com
- India growth set to near 2007 boom levels
Source: ft.com
- Speculators build record bets against euro
Source: ft.com













